top of page
Search

Lowering Dementia Risk: The 2026 National Plan and This Year's Research Results

4 days ago
6 min read

The federal government made dementia risk reduction its first national goal in October 2026, and new trial results show which steps have evidence behind them.


1. What Is New


On October 22, 2026, the U.S. Department of Health and Human Services (HHS) published the 2026 National Plan to Address Alzheimer's Disease and Related Dementias. HHS stated, "The updated plan puts greater emphasis on reducing dementia risk across the lifespan and translating scientific discoveries into better prevention, diagnosis, treatment, and care." The first of the plan's four goals is "Promote Dementia Risk Reduction Across the Lifespan."


Risk reduction is also moving into routine medical care. On October 6, 2026, the Alzheimer's Association launched the Brain Health & Quality Care Initiative. The Association stated, "Its first implementation focus is primary care, where many people first seek help for cognitive concerns."


Research published from July to October 2026 reports results on lifestyle, hearing and hormone therapy. A new trial will test a lifestyle program combined with a GLP-1 drug.


The federal position on prevention has not changed. The federal alzheimers.gov site states, "There are currently no approaches that have been proven to prevent Alzheimer’s disease and related dementias."


2. What the Research Says


The federal plan. HHS describes Goal 1 as follows: "Advance understanding of risk factors, support healthy aging, and put evidence into practice where it may help reduce risk or delay onset." The plan states, "A growing body of research has identified many modifiable risk factors for ADRD and suggests that addressing these risk factors may delay the onset or slow the progression of ADRD and its symptoms." ADRD means Alzheimer's disease and related dementias. The plan names the conditions: "There is growing evidence that chronic conditions and health behaviors that affect heart, vascular, and metabolic health, including high blood pressure, diabetes, high LDL cholesterol, obesity, smoking, physical inactivity, and excessive alcohol use, are also associated with cognitive decline and dementia risk." The plan states, "Managing conditions such as hypertension, diabetes, and depression and engaging in activities such as cognitive training and physical exercise may support both cognitive health and healthy aging." HHS also plans to "test a lifestyle intervention for beneficiaries with mild cognitive impairment."


Lifetime risk. JAMA reported on September 4, 2026, "According to a 2025 US estimate, the lifetime risk of dementia after age 55 years is 42%, with higher rates among women, Black adults, and carriers of the apolipoprotein ε4 (APOE ε4) allele, the primary genetic risk factor for sporadic Alzheimer disease." The 42% counts the estimated share of U.S. adults over age 55 who will develop dementia during their lifetime.


Lifestyle program (randomized trial). The LatAm-FINGERS trial was reported at the Alzheimer's Association International Conference (AAIC) on July 13, 2026. The Alzheimer's Association stated, "The study is also being published simultaneously in The Lancet." The trial enrolled 1,065 participants at 12 sites in 11 Latin American countries. The Association stated, "Participants were randomly assigned to one of two intervention groups." The systematic program included "supervised exercise, nutrition counseling based on an adapted MIND diet, computerized cognitive training" and other parts. The Association stated that the flexible group "received periodic health education and general lifestyle recommendations." The Association reported the two-year result: "The SLI group showed a 55% greater improvement on a composite measure of global cognition than the FLI group." SLI means the Systematic Lifestyle Intervention. The result is a thinking score, not a count of dementia diagnoses.


Lifestyle program plus a GLP-1 drug (new trial). On July 13, 2026, the Alzheimer's Association announced the PROTECT-Cog Study. The Association stated, "The PROTECT-Cog Study will enroll older adults who are at increased risk for cognitive decline." The study will test whether "a metabolism-targeting drug, such as a GLP-1 agonist, can further reduce the risk" when added to a lifestyle program. The Association stated, "Participants will be followed for three years, with comprehensive cognitive and health evaluations conducted every six months."


Hearing (randomized trial, secondary analysis). The journal eClinicalMedicine published a new analysis of the ACHIEVE trial in September 2026. The analysis included 164 participants. The intervention included "audiological counselling, provision of hearing aids" and other support. The authors stated, "Randomisation to hearing intervention was associated with a slower three-year rise in a blood-based biomarker of neuroinflammation." The authors also stated, "Replication in larger samples with more frequent sampling is needed." The result is a blood marker, not a count of dementia diagnoses.


Menopausal hormone therapy (observational study). On August 12, 2026, Stanford Medicine reported a study published in Neurology. Stanford Medicine reported, "Estrogen-only menopausal hormone therapy users had 39% lower odds than non-users of receiving a clinical diagnosis of dementia during their lifetimes, and they performed better on memory tests and in their overall ability to function independently." Stanford Medicine stated, "As a result, the findings are applicable only to estrogen-only formulation, not to estrogen-plus-progestin formulation and not to topical as opposed to oral estrogen administration." Stanford Medicine also stated, "And while the association with reduced Alzheimer’s risk is clear, it still doesn’t amount to definitive proof of causality."


3. What It Means for Families


The 2026 evidence falls into three groups.


Shown in randomized trials: a supervised lifestyle program improved thinking scores more than general advice. A hearing intervention slowed the rise of one blood marker.


Shown as association only: estrogen-only hormone therapy and lower odds of dementia.


Not yet tested: a lifestyle program combined with a GLP-1 drug.


No 2026 result proves that any single step prevents dementia. The conditions named in the National Plan are routine health matters that families can raise at a regular primary care visit.


4. What Doctors and Researchers Advise


1. The National Institute on Aging advises, "Control high blood pressure." It also advises, "Manage blood sugar."


2. The National Institute on Aging advises, "Take care of your mental and physical health." The Institute states, "This includes getting your recommended health screenings, managing chronic health issues such as depression or high cholesterol, and regularly checking in with your health care provider."


3. The National Institute on Aging advises, "Keep physically active." The Institute states, "Aim to get at least 150 minutes of moderate-intensity physical activity each week."


4. The National Institute on Aging advises, "Treat hearing problems." The Institute states, "Protect your ears from loud sounds to help prevent hearing loss and use hearing aids if needed."


5. The National Institute on Aging advises, "Sleep well." The Institute states, "Try to get seven to eight hours of sleep each night." It also advises, "Talk with your doctor if you are not getting enough sleep, sleeping poorly, or think you may have a sleep disorder."


6. The National Institute on Aging advises, "Stop tobacco use." The Institute states, "At any age, stopping smoking can improve your health and lower the risk of heart attack, stroke, and lung disease."


7. The National Institute on Aging advises, "Check with your doctor before trying any new medication or supplement."


8. The National Institute on Aging states, "Clinical trials need volunteers to help test strategies to diagnose, treat, and prevent dementia."


5. Sources



Help lines:



This newsletter reports published research and resources for informational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment. Consult a physician or other qualified health care provider with any questions about your own health or the health of a loved one.

Recent Posts

See All
Is Alzheimer's Care Designed for Everyone?

Access to Alzheimer's care is not determined by medical advances alone. Explore how institutional assumptions, unequal access, and gaps in professional training can affect who receives timely, appropr

 
 
bottom of page